Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2009-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-09-0323PMID 19584233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

  2009cited by this paper
• Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

  2009cited by this paper
• The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents

  2009cited by this paper
• ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture

  2008cited by this paper
• checkpoint: kinetochore-microtubule error correction and beyond

  2008cited by this paper
• Molecular basis of drug resistance in aurora kinases.

  2008cited by this paper
• Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.

  2008cited by this paper
• Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.

  2007cited by this paper
• Network modeling links breast cancer susceptibility and centrosome dysfunction.

  2007cited by this paper
• [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen].

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007influential reference
• MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy

  2007cited by this paper
• Chromosomal passengers: conducting cell division

  2007cited by this paper
• Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.

  2007cited by this paper
• PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

  2007cited by this paper
• Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

  2007influential reference
• VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells

  2007influential reference
• The spindle-assembly checkpoint in space and time

  2007cited by this paper
• The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.

  2006influential reference
• Validating Aurora B as an anti-cancer drug target

  2006cited by this paper
• Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis.

  2006cited by this paper
• Targeting aurora kinases as therapy in multiple myeloma.

  2006cited by this paper
• Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.

  2005cited by this paper
• Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol

  2005cited by this paper
• The Mitotic Spindle Checkpoint Is a Critical Determinant for Topoisomerase-based Chemotherapy*

  2005cited by this paper
• Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin

  2005cited by this paper
• Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.

  2005cited by this paper
• Aurora-A — A guardian of poles

  2005cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004influential reference
• Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint

  2004cited by this paper
• Aurora-kinase inhibitors as anticancer agents

  2004cited by this paper
• Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy

  2004cited by this paper
• Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint.

  2004cited by this paper
• RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

  2004cited by this paper
• The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint

  2003influential reference
• Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

  2003influential reference
• AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

  2003cited by this paper
• G1 tetraploidy checkpoint and the suppression of tumorigenesis

  2003cited by this paper
• Bax and BH3-domain-only proteins in p53-mediated apoptosis.

  2002cited by this paper
• MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells

  2001cited by this paper
• Role of BAX in the apoptotic response to anticancer agents.

  2000cited by this paper
• Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1

  2000cited by this paper
• Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

  1999cited by this paper
• Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

  1998cited by this paper
• AIM‐1: a mammalian midbody‐associated protein required for cytokinesis

  1998cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

  1998cited by this paper

• KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors

  2026cites this paper
• Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma

  2025cites this paper
• Survivin and Aurora Kinase A control cell fate decisions during mitosis.

  2025cites this paper
• Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents

  2024cites this paper
• Multidimensional analysis of the impact of Gemmatimonas, Rhodothermus, and Sutterella on drug and treatment response in colorectal cancer

  2024cites this paper
• The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer

  2024cites this paper
• Salviae miltiorrhiza against human lung cancer: A review of its mechanism (Review)

  2023cites this paper
• Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer

  2022cites this paper
• Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening

  2022cites this paper
• Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

  2022cites this paper
• Association between the morphokinetics of in-vitro-derived bovine embryos and the transcriptomic profile of the derived blastocysts

  2022cites this paper
• From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase.

  2021cites this paper
• Exploring the Conformational Landscape and Stability of Aurora A Using Ion-Mobility Mass Spectrometry and Molecular Modeling

  2021cites this paper
• Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies

  2021cites this paper
• CRISPR/Cas9 screening identifies a kinetochore‐microtubule dependent mechanism for Aurora‐A inhibitor resistance in breast cancer

  2021cites this paper
• Second-Generation Antimitotics in Cancer Clinical Trials

  2021cites this paper
• Cytotoxic and Anti-Plasmodial Activities of Stephania dielsiana Y.C. Wu Extracts and the Isolated Compounds

  2020cites this paper
• Biotransformation Pathways and Metabolite Profiles of Oral [C]-Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors Authors: Sandeepraj Pusalkar,

  2020cites this paper
• Screening and verifying key genes with poor prognosis in colon cancer through bioinformatics analysis

  2020cites this paper
• Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2020cites this paper
• Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells

  2019cites this paper
• Insights into the non-mitotic functions of Aurora kinase A: more than just cell division

  2019cites this paper
• Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells

  2019cites this paper
• Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.

  2019cites this paper
• Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species

  2019cites this paper
• Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

  2019cites this paper
• Survivin regulates chromosome segregation by modulating the phosphorylation of Aurora B during porcine oocyte meiosis

  2018cites this paper
• A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

  2018cites this paper
• Systematic Computational Design and Identification of Low Picomolar Inhibitors of Aurora Kinase A

  2018cites this paper
• Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase–TPX2 protein–protein interaction

  2017cites this paper
• Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.

  2017cites this paper
• Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆

  2017cites this paper
• Aurora-A promotes the establishment of spindle assembly checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase

  2017cites this paper
• Aurora-A Regulates Progression and Metastasis of Colorectal Cancer by Promoting Slug Activity

  2016cites this paper
• Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways.

  2016cites this paper
• Personalized Therapy of Small Cell Lung Cancer.

  2016cites this paper
• The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation

  2016cites this paper
• Aurora Kinase Inhibitors: Current Status and Outlook

  2015cites this paper
• Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition

  2015cites this paper
• The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells

  2015cites this paper
• Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer

  2015cites this paper
• Identifying mechanisms of resistance and potential therapeutic targets for pediatric acute myeloid leukemia

  2014cites this paper
• Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)

  2014cites this paper
• Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents

  2014cites this paper
• The Aurora Kinases in Cell Cycle and Leukemia

  2014cites this paper
• QUINASES EM CARCINOMA DE ADRENAL

  2014cites this paper
• Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells

  2014cites this paper
• Mecanismos Envolvidos com a Inibição de Aurora-Quinases em Carcinoma de Adrenal

  2014cites this paper
• Prognostic role of Aurora-A expression in metastatic colorectal cancer patients.

  2014cites this paper
• Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma

  2014cites this paper
• Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma

  2014cites this paper
• Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function

  2013cites this paper
• Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3

  2013cites this paper
• Structural and mechanistic insights into centromere specification and kinetochore regulation

  2013cites this paper
• Targeting aberrant kinase activity in myeloid leukaemias

  2013cites this paper
• Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

  2013cites this paper
• AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

  2013cites this paper
• Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells

  2013cites this paper
• Mitosis as an anti-cancer drug target

  2013cites this paper
• The spindle assembly checkpoint as a drug target - Novel small-molecule inhibitors of Aurora kinases

  2012cites this paper
• Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer

  2012cites this paper
• Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition

  2012cites this paper
• Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

  2012cites this paper
• The flavonoid eupatorin inactivates the mitotic checkpoint leading to polyploidy and apoptosis.

  2012cites this paper
• Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

  2012cites this paper
• The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

  2012cites this paper
• Current and Next Generation Antimitotic Therapies in Cancer

  2012cites this paper
• DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

  2012cites this paper
• An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

  2012cites this paper
• Possibility of the Use of Public Microarray Database for Identifying Significant Genes Associated with Oral Squamous Cell Carcinoma

  2012cites this paper
• Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2012cites this paper
• Aurora kinase B/C inhibition impairs malignant glioma growth in vivo

  2012cites this paper
• Tanshinones Inhibit the Growth of Breast Cancer Cells through Epigenetic Modification of Aurora A Expression and Function

  2012cites this paper
• Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death

  2012cites this paper
• Targeting aurora kinases in cancer treatment.

  2011cites this paper
• A systems pharmacology analysis of major chemotherapy combination regimens used in gastric cancer treatment: predicting potential new protein targets and drugs.

  2011cites this paper
• MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.

  2011cites this paper
• Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo.

  2011cites this paper
• Tanshinones as Effective Therapeutic Agents for Prostate Cancer

  2011cites this paper
• Mitosis as an anti-cancer target

  2011cites this paper
• Strategies for New Agent Development and Clinical Trial Considerations

  2011cites this paper
• Apoptosis and mitotic slippage following drug intervention in leukaemia cells

  2011cites this paper
• Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1

  2011cites this paper
• The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis

  2011cites this paper
• Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice

  2011cites this paper
• Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells

  2011cites this paper
• Response of experimental malignant melanoma models to the pan‐Aurora kinase inhibitor VE‐465

  2010cites this paper
• Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

  2010cites this paper
• Dissecting the role of INCENP-Aurora B in spindle assembly checkpoint function, chromosomal alignment and cytokinesis.

  2010cites this paper
• Chemotherapy and signaling

  2010cites this paper
• Shared and separate functions of polo-like kinases and aurora kinases in cancer

  2010cites this paper
• Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

  2010cites this paper
• Centromere localization of INCENP-Aurora B is sufficient to support spindle checkpoint function

  2010cites this paper
• Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.

  2010cites this paper
• Mitotic drug targets

  2010cites this paper
• Análise de redes de interações entre drogas quimioterápicas usadas no tratamento de câncer gástrico : explorando proteínas e processos biológicos por meio de ferramentas de farmacologia de sistemas

  2010cites this paper